Teva to face trimmed US antitrust claims from Mylan* over Copaxone
MLex Summary: Teva Pharmaceuticals was granted partial dismissal of third-party payors’ amended US antitrust claims accusing it of illegally delaying a generic competitor for multiple sclerosis-treatment drug Copaxone. District Judge Julien Xavier...To view the full article, register now.
Already a subscriber? Click here to view full article